Parkinson's disease (PD), also known as paralysis agitans, is a progressive neurodegenerative disease that commonly affects middle-aged and older people. Currently, neurological diseases are the leading cause of disability worldwide, and the incidence of PD is increasing rapidly. PD seriously affects quality of life and represents a great burden on patients, their families, and society as a whole. Epidemiological surveys show that PD is the second most common neurodegenerative disease after Alzheimer's disease.[5,6] Therefore, PD has become a significant medical and social concern.
PD typically develops in middle-age, with occult early onset and slow progression. The characteristic symptoms of PD are tremor, muscle rigidity, slow movements, and postural instability. Pathological changes in this disease include the degeneration and loss of dopaminergic neurons in the nigrostriatal region and the formation of Lewy bodies. Patients develop a series of clinical symptoms caused by this decrease in dopamine neurotransmitters. The pathogenesis of PD is complex and diverse, and include environmental and genetic factors, mitochondrial dysfunction, oxidative stress, and inflammatory responses. Several genes have been reported to be associated with PD, including PARKIN (also known as PARK2), PINK1 (also known as PARK6), DJ-1 (also known as PARK7), VPS35, LRRK2 (also known as PARK8), ATPl3A2 (also known as PARK9), UCHL1 (also known as PARK5), GBA1, and SNCA (also known as PARK4, this encodes the α-synuclein protein).
Mutations in PARKIN, PINKl, DJ-1, and VPS35 impair mitochondrial function and affect neuronal activity.LRRK2 regulates mitochondrial function, autophagy, and neuroinflammation, and mutations in this gene can cause the degeneration of dopaminergic neurons. Mutations in ATP13A2 affect cellular oxygen consumption and mitochondrial membrane potential while GBA1 mutations increase the likelihood of developing GBA1-related PD. Mutations in SNCA result in the abnormal expression of α-synuclein, which aggregates in neurons, forming Lewy bodies. Released α-synuclein activates microglia and induces the increased production of reactive oxygen species (ROS) and inflammatory mediators such as interleukin 13 and tumor necrosis factor α, which promote inflammatory responses and exacerbate degenerative lesions in dopaminergic neurons. Increased neuronal concentrations of α-synuclein can induce metabolic disorders, lipid peroxidation, protein and DNA damage, and eventually the degeneration of dopaminergic neurons. Thus, the protection of mitochondrial function, reduction of oxidative stress, and inhibition of inflammatory responses are critical components of new strategies for the treatment of PD. Currently, the main treatments for PD include surgery, rehabilitation, acupuncture, and nursing; however, the most commonly used treatments are drug therapies (Fig. 1).
The main therapeutic drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase-B inhibitors, catechol oxymethyltransferase inhibitors, and other ancillary drugs; however, all of these drugs cause significant adverse reactions. Therefore, the identification and development of new drugs for the treatment of PD is urgently required.
Metformin is the first-line treatment for type 2 diabetes according to many guidelines. Its main pharmacological action is to inhibit hepatic glucose output, to improve the sensitivity of peripheral tissues to insulin, and increase the uptake and use of glucose to lower blood sugar levels. Metformin exerts multi-faceted regulatory functions by activating the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway. In addition to treating type 2 diabetes, metformin is also effective against other diseases. In the cardiovascular system, the drug can inhibit the formation of atherosclerosis, regulate blood pressure and blood lipids, and control body weight.[21–23] Metformin application has also been reported in conditions such as pre-eclampsia and congestive heart failure.[24,25] Furthermore, in the female reproductive system, the drug has clinical efficacy in the treatment of polycystic ovary syndrome and gestational diabetes, as well as in the adjuvant treatment of breast cancer, ovarian cancer, endometrial cancer, and a variety of other female reproductive system tumors.[26–28] In addition, metformin is potentially effective in the treatment of nonalcoholic steatohepatitis, tubulointerstitial fibrosis, and multiple sclerosis.[29–31] Metformin also plays a positive role in neuroprotection by mediating the inhibition of inflammatory responses, improving cognitive impairment, and treating some forms of autism. These results highlight its potential application in the treatment of PD.[32–35]
Database search strategy
The authors included studies that discussed the potential role of metformin in the treatment of PD. English language and full-text articles published between 2002 and 2019 were included in this non-systematic review. The authors searched the PubMed database to identify relevant publications. Publications were chosen that specifically discussed inducing plasticity with the following terms: metformin, PD, type 2 diabetes, neuroprotective effects, and AMPK. The results were further screened by title and abstract for comorbidity of PD and diabetes, the neuroprotective effects of metformin, or metformin treatment of PD. The data extraction process focused on the neural effects of metformin and the potential role of metformin in the treatment of PD.
Comorbidity of Parkinson's disease and diabetes
Both PD and diabetes are associated with environmental factors and have genetic susceptibility.[36–38] The incidence of both chronic diseases is age-related, and they are both associated with similar metabolic disorders and pathogenic pathways.[39–41] There is increasing evidence that PD susceptibility is increased in patients with type 2 diabetes, and PD patients often have co-existing insulin resistance. As shown in Figure 2, there is a significant link between PD and the pathogenesis of diabetes according to the aforementioned relevant publications.
PD has similar risk factors and genetic susceptibility to diabetes
It has been proposed that environmental factors such as metal ions, including iron and zinc, are important risk factors for PD and Alzheimer's disease; diabetes risk is also increased by exposure to heavy metals such as zinc, manganese, cadmium which affects glucose homeostasis. In terms of genetic susceptibility, α-glucosidase is an important factor affecting peripheral blood glucose fluctuations in patients with type 2 diabetes, and mutations in the glucosidase gene in the brain are closely related to neurological dysfunction in PD patients. PD can also be caused by mutations in DJ-1, which regulates astrocyte hyperplasia by activating the signal transduction and activator of transcription-3 pathway; DJ-1 expression is reduced in the islet cells of type 2 diabetic patients. This evidence suggests a molecular basis for the comorbidity of PD and diabetes.
PD has a similar pathogenesis to diabetes
An epidemiological investigation into insulin resistance revealed a significant increase in body weight in PD patients after diagnosis. In PD patients with dementia, 30% had impaired glucose tolerance, 5.6% were diagnosed with diabetes, and 26% had insulin resistance only. In addition, a phenomenon similar to the process of peripheral insulin resistance occurs in the brain of PD patients, suggesting that the insulin resistance may be an important factor in PD pathogenesis. It has been shown that increased ferritin and impaired glucose homeostasis might increase the risk of diabetes, and these ions are known to generate large amounts of free radicals via the Fenton reaction, thus causing the degeneration of dopaminergic neurons. Therefore, iron metabolism might be a common factor related to both diabetes and PD. Insulin receptors are also present in the basal ganglia and substantia nigra, and insulin plays an important role in neuronal survival, growth, and regeneration, as well as in neurotrophy, neuromodulation, and synapse maintenance.[54–56] Dopaminergic neuron degeneration is the most important pathological change in PD, and insulin resistance in the brain can induce the dysfunction of mitochondria and dopaminergic neurons. Pyramidal neurons in the cerebral cortex, hippocampus, and olfactory bulb produce insulin-like growth factors (IGFs), and downregulation of IGF-1 signaling can lead to cognitive impairment in vascular dementia. Therefore, IGF-1 deficiency may be associated with the development and progression of neurodegenerative diseases. In addition, protein kinase B (also known as Akt), which is an important downstream target of the insulin signaling pathway, is also closely related to PD. Akt associates with mammalian target of rapamycin (mTOR) to form the Akt-mTOR axis, which is considered central to the insulin signaling cascade. In addition, the Akt signaling pathway plays a central role in insulin-stimulated glucose metabolism and cell survival. AMPK is a key regulator of mitochondrial synthesis but it is also a neuroprotective factor. AMPK expression is decreased in patients with insulin resistance, which leads to impaired mitochondrial function, damaged cell structures, and ultimately, the death of dopaminergic neurons. Thus, improving insulin resistance may be a potential therapeutic target in the treatment of neurodegenerative diseases.
Under conditions of cellular oxidative–reductive (redox) imbalance, oxidative stress damages cell membranes and other biomolecules, and is associated with a variety of neurological diseases.[64–66] Dopamine is highly susceptible to oxidation, a reaction that is thought to be the main cause of PD by directly causing neuronal damage and progressive degeneration of dopaminergic neurons in the nigrostriatal region of the brain. Studies have shown that ROS influence glucose metabolism by upregulating the pentose pathway, thereby inducing insulin resistance in patients with type 2 diabetes. The production of reactive oxygen species (ROS) leads to oxidative stress, causing the death of dopaminergic neurons and the partial discharge of their cell contents. One cause of oxidative stress is the upregulation of nitric oxide synthase (NOS), which exists in 3 forms: inducible NOS, endothelial NOS, and neuronal NOS (nNOS). single nucleotide polymorphisms in NOS1 can modify NO production in neurons and may be associated with neurological diseases. DNA damage is a proposed pathogenic factor for PD, and a previous study showed that both cyclooxygenase-2 and nNOS interact with oxidative stress to cause DNA damage in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model. All of these factors suggest that NOS may induce oxidative stress, thus causing cognitive impairment in PD patients. Factors involved in the molecular mechanisms of oxidative stress include changes in DJ-1 expression, mitochondrial dysfunction, and excitatory toxicity of N-methyl-D-aspartate receptors induced by glutamate overstimulation. N-methyl-D-aspartate receptor overstimulation causes extracellular Ca2+ influx, resulting in nNOS activation. Activated nNOS produces nitric oxide and reacts with other ROS to form highly toxic peroxynitrites, which cause protein nitrification, lipid peroxidation, and DNA fragmentation to induce cellular damage. Therefore, oxidative stress is likely to be a common factor in the pathogenesis of both insulin resistance in type 2 diabetes and dopaminergic neuronal damage in PD.
Inflammation is also associated with the onset of type 2 diabetes and insulin resistance. Furthermore, inflammation has also been identified as a major risk factor for PD, both genetically and because the secretion of high levels of pro-inflammatory mediators from chronic microglia activation cause neuronal damage and promote neurodegeneration. Therefore, anti-inflammatory immunomodulatory therapy may become an important approach for the prevention and control of PD and its complications.
Type 2 diabetes increases PD risk
Multiple epidemiological cohort studies have revealed a significant increase in PD risk in patients with type 2 diabetes. Both PD and diabetes have a high prevalence in the older population. PD patients with diabetes show increased dopamine release compared with PD patients without diabetes. The simultaneous presence of diabetes in patients with PD may accelerate the deposition of amyloid plaques in the brain or exacerbate brain atrophy, causing severe cognitive impairment in PD patients.[84,85] Other studies have indicated that the presence of diabetes leads to more severe cognitive dysfunction, postural instability, and gait difficulty via mechanisms other than the nigrostriatal dopaminergic neuron degeneration that typically occurs in patients with PD[86,87]; however, the specific mechanism remains to be clarified. In addition, diabetes may be associated with more severe motor impairment in PD. Although the mechanisms of PD are complex, the association between type 2 diabetes and PD may provide a new direction for the development of therapeutic strategies in PD.
Neuroprotective effects of metformin
Insulin is a polypeptide secreted by islet β cells. In addition to its unique hypoglycemic function, the role of insulin in the nervous system is attracting increasing attention. Insulin contributes to the development and repair of nerves by signaling via the tyrosine kinase receptor pathways. Insulin signaling in the nucleus alters the expression of axon-related proteins and drives the regeneration of distal axons. In a rat model of insulin-deficient type 1 diabetes, the sustained delivery of exogenous insulin restored the normal function of damaged nerves and protected the central nervous system from damage. Additionally, retinal neuron regeneration in type 1 diabetes patients can be promoted by treatment with insulin eye drops or intravenous infusion, and the use of insulin and metformin to treat patients with gestational diabetes can effectively control blood glucose levels and reduce the incidence of abnormal neurodevelopment in neonates. Thus, there is substantial evidence that insulin metabolism can influence the development, regulation, and repair of the nervous system.
Diabetes comprises a group of metabolic diseases characterized by hyperglycemia, mainly caused by impaired insulin secretion or its biological effects, or both. This condition causes chronic damage and dysfunction in various tissues due to long-term hyperglycemia. Diabetic peripheral neuropathy and diabetic encephalopathy are important complications in the nervous system in this disease, suggesting that the drugs used to treat diabetes may also have an impact on neurological diseases.[93,94]
Metformin is a hypoglycemic drug that improves insulin resistance and regulates insulin metabolism, and which is advantageous because it has few side effects and is cheap to purchase. Early studies showed that metformin not only reduces blood sugar levels, but also directly inhibits the formation of advanced glycation end-products, thus effectively preventing diabetes complications. Subsequent studies showed that metformin promotes nerve regeneration after diabetic sciatic nerve injury, thus reflecting its therapeutic value for the repair of diabetic peripheral nerve injury. Recently, autophagy was identified as an intracellular catabolic process with neuroprotective properties. One study reported that metformin enhances autophagy by inhibiting apoptosis and inflammation via the mammalian target of the rapamycin (mTOR)/p70S6 kinase (p70S6K) signaling pathway, thereby exerting neuroprotective effects in spinal cord injury in rats. Metformin can also effectively improve the glucose uptake function of insulin-resistant neuronal cells by activating AMPK, insulin receptor β subunit (IRβ), insulin receptor substrate 1, and phosphatidylinositol 3 kinase. Furthermore, metformin has been shown to exert neuroprotective effects against primary neuronal apoptosis. It can also reduce subgranulocyte proliferation and normalize neuroblast differentiation in the hippocampal dentate gyrus in a diabetic rat model. In a rat model of anxiety established using methamphetamine, metformin exerted antioxidant effects and upregulated antioxidant enzymes (such as superoxide dismutase and glutathione), suggesting that metformin reduces methamphetamine-induced neurodegenerative changes via the cyclic adenosine monophosphate response element-binding protein (CREB)/brain-derived neurotrophic factor (BDNF) or Akt/glycogen synthase kinase-3 pathways. One study also reported that metformin improves cognitive impairment and reduces oxidative stress in the brains of mice with generalized convulsive seizures induced by acute pentylenetetrazole. Chronic L-methionine administration causes hyperhomocysteinemia and impaired memory, and a previous study in rats reported that metformin may restore L-methionine-induced memory impairment by normalizing oxidative stress levels in the hippocampus. Metabolic memory, which refers to persistent diabetic stress even after the normalization of blood glucose, is a major cause of diabetic complications. A glucagon-like peptide-1 receptor agonist can alleviate neuronal damage and reduce neuronal metabolic memory in animal models of diabetes-related dementia. Glucagon-like peptide-1 receptor agonist treatment also promotes neuronal growth and repair and reduces inflammation, apoptosis, and oxidative stress, and treatment with glucagon-like peptide-1 analogs and metformin improves cognitive impairment. The long-term consumption of a high-fat diet (HFD) in rat models causes insulin resistance, and a HFD consumption also causes brain mitochondrial dysfunction and cognitive impairment. Metformin could completely restore brain mitochondrial function in these long-term HFD rat models, and also restored the learning and memory behaviors that were impaired by long-term HFD consumption. Damage caused by factors such as increased oxidative stress, blood–brain barrier disruption, inflammation, and mitochondrial dysregulation, may result in neuronal death. A recently review shows that metformin may improve functional recovery via these mechanisms following experimental cerebral ischemia/reperfusion injury. Furthermore, metformin activates an atypical protein kinase C–CREB-binding protein pathway, promotes neurogenesis and spatial memory formation, and effectively improves memory impairment in type 2 diabetic male db/db mice with hyperinsulinemia. A recent study also reported that saffron and metformin combination therapy improves learning and memory disorders in streptozotocin-induced diabetic rats via a mechanism that may involve the inhibition of oxidation, inflammation, and apoptosis, among other processes. In addition to its neuroprotective effects in diabetic patients, studies have also indicated a protective function against experimental acrylamide-induced neurological disease in rats via its effects in restoring lipid peroxidation in the brain and spinal cord, reducing caspase-3 protease activity, and upregulating Bcl-2 expression in the brain and sciatic nerve. Painful diabetic neuropathy is a common complication in patients with diabetes, often causing severe hyperalgesia and analgesia. In a study of hyperalgesia and analgesia pain-induced diabetic neuropathy in a streptozotocin-induced diabetic rat model, metformin was shown to activate the AMPK pathway in the sciatic nerve by increasing AMPK expression and via the antioxidant effects of the AMPK signaling pathway, thus leading to the amelioration of painful diabetic neuropathy. However, metformin may cause vitamin deficiency in the treatment of type 2 diabetes; therefore, to avoid exacerbating neurological damage with depression or cognitive decline, it may be necessary to screen for cobalamin deficiency in patients with diabetes who are taking metformin. Overall, metformin promotes autophagy, has anti-inflammatory, antioxidative, and anti-apoptotic effects on the nervous system, and exerts neuroprotective effects through activation of the AMPK, caspase-3, Bcl-2, mTOR/p70S6K, CREB/BDNF, and Akt/glycogen synthase kinase-3 signaling pathways (Table 1).
Metformin treatment of Parkinson's disease
Studies have shown that anti-diabetic drugs promote neuronal survival, affect brain metabolism and nerve inflammation and regeneration, and lead to improved memory and cognition. Therefore, antidiabetic drugs are potential therapeutic agents for the treatment of neurological diseases. Metformin is a first-line hypoglycemic agent for the treatment of insulin-resistant (type 2) diabetes mellitus. The role of metformin in cell metabolism, neuronal protection, and improvement of cognitive impairment suggests that metformin may alleviate, or even cure, PD-related symptoms (Fig. 3).
Metformin increases neurogenesis and spatial memory formation and reduces the risk of PD. Metformin also prevents haloperidol-induced hydrogen peroxide formation by inhibiting oxidation/nitrification stress, suggesting an adjuvant role in the treatment of PD. Furthermore, metformin has neuroprotective effects in the MPTP mouse model of PD, with long-term metformin treatment resulting in significantly improved movement and muscle activity compared with the effects of short-term treatment. Furthermore, compared with the MPTP-negative control group, both the antioxidative activity of metformin and BDNF levels were significantly improved. Other studies have shown that metformin is neuroprotective against the neurotoxic effects of MPTP by inhibiting α-synuclein phosphorylation and increasing BDNF levels in the substantia nigra. These experiments in animal models provide preclinical support for the treatment of PD with metformin.
Metformin exerts its neuroprotective effects mainly by activating the AMPK–autophagy signaling pathway and inhibiting metabolic inflammation, which represents a therapeutic target in PD. The decreased activity of neural stem cells in older people is associated with the decreased expression of AMPK and mitochondria-associated genes/proteins (eg, peroxisome proliferator-activated receptor γ coactivator-1α, nuclear respiratory factor-1, mitochondrial transcription factor A (Tfam)) and the increased activity of caspase-3 and caspase-9. Metformin prevents the aging-induced release of cytochrome C from the mitochondria into the cytosol in human neural stem cells. Co-treatment with metformin abolishes the effects of aging on human high cervical myeloid cells and significantly reverses the decreased expression levels of senescence-related neuroprotective genes (PPARγ, Bcl-2, CREB). Results from these studies indicate the potential of the AMPK pathway as a therapeutic target for the treatment of diabetic neurodegeneration.
However, the long-term use of metformin slightly increases the risk of Alzheimer's disease and vascular dementia.[121,122] The decrease in BDNF suggests a potential state of vulnerability for the brain, as well as a decrease in neuroplasticity, which is necessary for enhanced cognitive effects. Long-term use of metformin reduces BDNF transcription and inhibits nuclear factor E2-related factor 2 (Nrf2), which may increase the vulnerability of the central nervous system. Some studies have also suggested that metformin increases the risk of PD or even aggravates neuronal damage. For example, metformin inhibited the MPTP-induced brain inflammatory response through iNOS, IL-1β, and TNF-α, affecting the microglia polarization state under conditions of neurodegeneration. However, MPTP and metformin may act in an additive manner to inhibit complex I of the electron transport chain in Parkinsonian patients, thus reducing ATP levels. Despite inflammatory parameters being decreased, a dose of MPTP lower than that of metformin may increase neuronal damage and exacerbate the vulnerability of neurons, which are particularly sensitive to the inhibition of complex I in the electron transport chain.
Therefore, the indications for the safe use of this drug therapy should be carefully controlled for patients requiring long-term and high-dose treatment with metformin.
By reviewing the occurrence, development, and biochemical changes of PD, as well as the possible mechanisms underlying the effects of metformin on various aspects of PD (especially in the nervous system), we have revealed the potential link between PD and metformin. This information provides a theoretical basis for the treatment of PD with metformin. Moreover, advances in the fields of epidemiology, animal models, and molecular biology have facilitated the accumulation of evidence to support the therapeutic potential of metformin in PD.
Metformin significantly improves insulin resistance in patients with PD, prevents further neuronal damage in PD patients with comorbid diabetes, and plays a role in neuroprotection and cognitive impairment. Metformin is associated with multiple signaling pathways, including the AMPK, caspase-3, Bcl-2, and mTOR/p70S6K pathways, which have anti-inflammatory, anti-oxidative, and anti-apoptotic effects, and promote autophagy, alleviate neuronal damage, reduce complications, and delay disease progression in PD patients. Therefore, the use of metformin for the treatment of PD has the potential for broad application.
Unfortunately, the pathogenesis of PD is still unclear, mainly because of its complexity. Although metformin has many advantages, certain problems and challenges remain in its clinical application for the treatment of PD.
In summary, current studies into the treatment of PD with metformin are mostly in the preclinical stage of animal experimentation. Most of these studies indicate the benefits of metformin in treating PD, but the use of metformin in clinical treatment remains to be verified.
We are indebted to all the individuals who participated in, or helped with, our work.
JM and ML designed the manuscript. HC, FN, XW, and ZT collected the data. ML and FN drew the figures. ML, HC and JM wrote the initial draft of the manuscript. All authors approved the final version of the manuscript.
This work was supported by the Natural Science Basic Research Plan in Shaanxi Province of China (No. 2019JM-098, to JM), the National Natural Science Foundation of China (No. 31371298, 81301151, to JM), Opening Project of the Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi’an Jiaotong University, China (No. 2017LHM-KFKT007, to JM), the National Innovation Experiment Program for University Students (No. GJ201810698126, to JM).
Conflicts of interest
The authors declare that they have no conflicts of interest.
. Radhakrishnan D, Goyal V. Parkinson's disease: a review. Neurol India 2018;66:S26–S35.
. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:939–953.
. Falup-Pecurariu C, Diaconu Ş. Sleep dysfunction in Parkinson's disease. Int Rev Neurobiol 2017;133:719–742.
. Yang JX, Chen L. Economic burden analysis of Parkinson's disease patients in China. Parkinsons Dis 2017;2017:8762939.
. Schapira AHV. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol 2013;26:395–400.
. Chou KL, Zamudio J, Schmidt P, et al. Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord 2011;17:440–445.
. Reich SG, Savitt JM. Parkinson's disease. Med Clin North Am 2019;103:337–350.
. Duda J, Pötschke C, Liss B. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. J Neurochem 2016;139 (Suppl 1):156–178.
. Bender E. In the clinic-Parkinsonʼs disease: bilateral deep brain stimulation improves non-motor symptoms of Parkinsonʼs disease two years after surgery. Neurol Today 2018;18:13–18.
. Talan J. Disease mechanisms-Parkinsonʼs disease: activity in genomic dark matter offers clues to nonmotor symptoms in Parkinsonʼs and neuropsychiatric disease. Neurol Today 2018;18.
. Raza C, Anjum R, Shakeel NUA. Parkinson's disease: mechanisms, translational models and management strategies. Life Sci 2019;226:77–90.
. Wang W, Wang X, Fujioka H, et al. Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med 2016;22:54–63.
. Ho DH, Je AR, Lee H, et al. LRRK2 kinase activity induces mitochondrial fission in microglia via Drp1 and modulates neuroinflammation. Exp Neurobiol 2018;27:171–180.
. Park J-S, Koentjoro B, Klein C, et al. Single heterozygous ATP13A2 mutations cause cellular dysfunction associated with Parkinson's disease. Mov Disord 2018;33:852–854.
. Stojkovska I, Krainc D, Mazzulli JR. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. Cell Tissue Res 2018;373:51–60.
. Volpicelli-Daley LA, Luk KC, Lee VMY. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc 2014;9:2135–2146.
. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261–309.
. Moin T, Schmittdiel JA, Flory JH, et al. Review of metformin use for type 2 diabetes
prevention. Am J Prev Med 2018;55:565–574.
. Zhou T, Xu X, Du M, et al. A preclinical overview of metformin for the treatment of type 2 diabetes
. Biomed Pharmacother 2018;106:1227–1235.
. Stephenne X, Foretz M, Taleux N, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011;54:3101–3110.
. Petrie JR, Chaturvedi N, Ford I, et al. Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial. Diabetes Obes Metab 2017;19:509–516.
. Thomopoulos C, Katsimagklis G, Makris T. Metformin and blood pressure lowering: a questioned association. J Hypertens 2017;35:27–28.
. Kyler KE, Kadakia RB, Palac HL, et al. Use of metformin for weight management in children and adolescents with obesity in the clinical setting. Clin Pediatr (Phila) 2018;57:1677–1685.
. Romero R, Erez O, Hüttemann M, et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol 2017;217:282–302.
. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 2017;166:191–200.
. Alzaid A, Tourkmani A, Alsahaby A, et al. Metformin therapy improves cognitive function in women with polycystic ovary syndrome (PCOS). Diabetologia 2017;1:S581–S582.
. Tripathi R, Tyagi S, Goel V. Metformin in gestational diabetes mellitus. Indian J Med Res 2017;145:588–591.
. Mallik R, Chowdhury TA. Metformin in cancer. Diabetes Res Clin Pract 2018;143:409–419.
. Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther 2014;31:30–43.
. Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol 2016;73:520–528.
. Wang M, Weng X, Guo J, et al. Metformin alleviated EMT and fibrosis after renal ischemia-reperfusion injury in rats. Ren Fail 2016;38:614–621.
. Lin C-H, Cheng Y-C, Nicol CJ, et al. Activation of AMPK is neuroprotective in the oxidative stress by advanced glycosylation end products in human neural stem cells. Exp Cell Res 2017;359:367–373.
. Han J, Li Y, Liu X, et al. Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS One 2018;13:e0193031.
. Ahuja S, Uniyal A, Akhtar A, et al. Alpha lipoic acid and metformin alleviates experimentally induced insulin resistance and cognitive deficit by modulation of TLR2 signaling. Pharmacol Rep 2019;71:614–623.
. Wang L, Cai Y, Fan X. Metformin administration during early postnatal life rescues autistic-like behaviors in the BTBR T+ Itpr3tf/J mouse model of autism. Front Behav Neurosci 2018;12:290.
. Campêlo CLC, Santos JR, Silva AF, et al. Exposure to an enriched environment facilitates motor recovery and prevents short-term memory impairment and reduction of striatal BDNF in a progressive pharmacological model of parkinsonism in mice. Behav Brain Res 2017;328:138–148.
. Soto-Ortolaza AI, Ross OA. Genetic susceptibility variants in parkinsonism. Parkinsonism Relat Disord 2016;22 (Suppl 1):S7–S11.
. Morris AP. Progress in defining the genetic contribution to type 2 diabetes
susceptibility. Curr Opin Genet Dev 2018;50:41–51.
. Zhu F, Li C, Gong J, et al. The risk of Parkinson's disease in inflammatory bowel disease: a systematic review and meta-analysis. Dig Liver Dis 2019;51:38–42.
. Nanayakkara N, Ranasinha S, Gadowski A, et al. Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes
. J Diabetes Complications 2018;32:279–290.
. Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med 2013;19:176–186.
. Delamarre A, Meissner WG. Epidemiology, environmental risk factors and genetics of Parkinson's disease. Presse Med 2017;46:175–181.
. Schelp AO, Mendes-Chiloff CL, Paduan VC, et al. Amnestic dementia impairment in Parkinson's disease: the role of body composition, ageing and insulin resistance. Clin Nutr ESPEN 2017;20:47–51.
. Wojtunik-Kulesza K, Oniszczuk A, Waksmundzka-Hajnos M. An attempt to elucidate the role of iron and zinc ions in development of Alzheimer's and Parkinson's diseases. Biomed Pharmacother 2019;111:1277–1289.
. Dover EN, Patel NY, Stýblo M. Impact of in vitro heavy metal exposure on pancreatic β-cell function. Toxicol Lett 2018;299:137–144.
. Osonoi T, Saito M, Mochizuki K, et al. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes
mellitus. Metabolism 2010;59:1816–1822.
. Del Sorbo F, Elia AE, Romito LM, et al. Autonomic dysfunction in Parkinson's disease associated with common glucocerebrosidase gene mutations. Parkinsonism Relat Disord 2016;22:e26.
. Choi DJ, Kwon JK, Joe EH. A Parkinson's disease gene, DJ-1, regulates astrogliosis through STAT3. Neurosci Lett 2018;685:144–149.
. Jain D, Jain R, Eberhard D, et al. Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes
. J Mol Cell Biol 2012;4:221–230.
. Vikdahl M, Carlsson M, Linder J, et al. Weight gain and increased central obesity in the early phase of Parkinson's disease. Clin Nutr 2014;33:1132–1139.
. Bosco D, Plastino M, Cristiano D, et al. Dementia is associated with insulin resistance in patients with Parkinson's disease. J Neurol Sci 2012;315:39–43.
. Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today 2016;21:802–818.
. Tian T, Ji-Chao Z, Lei H, et al. Synchrotron radiation X-ray fluorescence analysis of Fe, Zn and Cu in mice brain associated with Parkinson's disease. He Jishu: Yingwen Ban 2015;26:100–105.
. Lázár BA, Jancsó G, Pálvölgyi L, et al. Insulin confers differing effects on neurite outgrowth in separate populations of cultured dorsal root ganglion neurons: the role of the insulin receptor. Front Neurosci 2018;12:732.
. Byrne AB, Walradt T, Gardner KE, et al. Insulin/IGF1 signaling inhibits age-dependent axon regeneration. Neuron 2014;81:561–573.
. Bassil F, Fernagut PO, Bezard E, et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 2014;118:1–18.
. Kleinridders A, Cai W, Cappellucci L, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A 2015;112:3463–3468.
. Gong X, Ma M, Fan X, et al. Down-regulation of IGF-1/IGF-1R in hippocampus of rats with vascular dementia. Neurosci Lett 2012;513:20–24.
. Castilla-Cortázar I, Iturrieta I, García-Magariño M, et al. Neurotrophic factors and their receptors are altered by the mere partial IGF-1 deficiency. Neuroscience 2019;404:445–458.
. Timmons S, Coakley MF, Moloney AM, et al. Akt signal transduction dysfunction in Parkinson's disease. Neurosci Lett 2009;467:30–35.
. Ren L, Zhou X, Huang X, et al. The IRS/PI3K/Akt signaling pathway mediates olanzapine-induced hepatic insulin resistance in male rats. Life Sci 2019;217:229–236.
. Sun W, Yang J, Wang W, et al. The beneficial effects of Zn on Akt-mediated insulin and cell survival signaling pathways in diabetes. J Trace Elem Med Biol 2018;46:117–127.
. Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: a new target for disease modification? Prog Neurobiol 2016;145-146:98–120.
. Elfawy HA, Das B. Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: etiologies and therapeutic strategies. Life Sci 2019;218:165–184.
. Ranjan A, Kalita J, Kumar V, et al. MRI and oxidative stress markers in neurological worsening of Wilson disease following penicillamine. Neurotoxicology 2015;49:45–49.
. Díaz-Hung ML, González Fraguela ME. Oxidative stress in neurological diseases: cause or effect? Neurologia 2014;29:451–452.
. Ott T, Nieder A. Dopamine and cognitive control in prefrontal cortex. Trends Cogn Sci 2019;23:213–234.
. Meder D, Herz DM, Rowe JB, et al. The role of dopamine in the brain - lessons learned from Parkinson's disease. Neuroimage 2019;190:79–93.
. Dong K, Ni H, Wu M, et al. ROS-mediated glucose metabolic reprogram induces insulin resistance in type 2 diabetes
. Biochem Biophys Res Commun 2016;476:204–211.
. Tan SH, Karri V, Tay NWR, et al. Emerging pathways to neurodegeneration: dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease. Biomed Pharmacother 2019;111:765–777.
. Buchwalow I, Schnekenburger J, Atiakshin D, et al. Oxidative stress and NO generation in the rat pancreatitis induced by pancreatic duct ligation. Acta Histochem 2017;119:252–256.
. Gupta SP, Kamal R, Mishra SK, et al. Association of polymorphism of neuronal nitric oxide synthase gene with risk to Parkinson's disease. Mol Neurobiol 2016;53:3309–3314.
. Hoang T, Choi DK, Nagai M, et al. Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radical Biol Med 2009;47:1049–1056.
. Oh SE, Mouradian MM. Cytoprotective mechanisms of DJ-1 against oxidative stress through modulating ERK1/2 and ASK1 signal transduction. Redox Biol 2018;14:211–217.
. Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta Mol Basis Dis 2017;1863:1066–1077.
. Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 2009;1792:643–650.
. Domingueti CP, Dusse LM, Carvalho Md, et al. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications 2016;30:738–745.
. Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 2012;18 (Suppl 1):S207–S209.
. Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson's disease. Neuroscience 2015;302:89–102.
. Collins LM, Toulouse A, Connor TJ, et al. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 2012;62:2154–2168.
. De Virgilio A, Greco A, Fabbrini G, et al. Parkinson's disease: autoimmunity and neuroinflammation. Autoimmun Rev 2016;15:1005–1011.
. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 2016;15:1257–1272.
. Chung SJ, Jeon S, Yoo HS, et al. Detrimental effect of type 2 diabetes
mellitus in a large case series of Parkinson's disease. Parkinsonism Relat Disord 2019;64:54–59.
. Ong M, Foo H, Chander RJ, et al. Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson's disease. J Neurol Sci 2017;377:122–126.
. Petrou M, Davatzikos C, Hsieh M, et al. Diabetes, gray matter loss, and cognition in the setting of Parkinson disease. Acad Radiol 2016;23:577–581.
. Bohnen NI, Kotagal V, Müller ML, et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 2014;20:1394–1398.
. Kotagal V, Albin RL, Müller MLTM, et al. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 2013;19:522–526.
. Giuntini M, Baldacci F, Del Prete E, et al. Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. Parkinsonism Relat Disord 2014;20:671–672.
. Toth C, Brussee V, Martinez JA, et al. Rescue and regeneration of injured peripheral nerve axons by intrathecal insulin. Neuroscience 2006;139:429–449.
. King MR, Anderson NJ, Liu C, et al. Activation of the insulin-signaling pathway in sciatic nerve and hippocampus of type 1 diabetic rats. Neuroscience 2015;303:220–228.
. Agostinone J, Alarcon-Martinez L, Gamlin C, et al. Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury. Brain 2018;141:1963–1980.
. Van Dam JM, Garrett AJ, Schneider LA, et al. Reduced cortical excitability, neuroplasticity, and salivary cortisol in 11-13-year-old children born to women with gestational diabetes mellitus. EBioMedicine 2018;31:143–149.
. Giatti S, Mastrangelo R, D’Antonio M, et al. Neuroactive steroids and diabetic complications in the nervous system. Front Neuroendocrinol 2018;48:58–69.
. Patrone C, Eriksson O, Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014;2:256–262.
. Tanaka Y, Uchino H, Shimizu T, et al. Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol 1999;376:17–22.
. Ma J, Liu J, Yu H, et al. Beneficial effect of metformin on nerve regeneration and functional recovery after sciatic nerve crush injury in diabetic rats. Neurochem Res 2016;41:1130–1137.
. Wang C, Liu C, Gao K, et al. Metformin preconditioning provide neuroprotection through enhancement of autophagy and suppression of inflammation and apoptosis after spinal cord injury. Biochem Biophys Res Commun 2016;477:534–540.
. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011;60:910–920.
. El-Mir MY, Detaille D, R-Villanueva G, et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 2008;34:77–87.
. Hwang IK, Kim IY, Joo EJ, et al. Metformin normalizes type 2 diabetes
-induced decrease in cell proliferation and neuroblast differentiation in the rat dentate gyrus. Neurochem Res 2010;35:645–650.
. Huang YC, Hsu CC, Lin WC, et al. Effects of metformin on the cerebral metabolic changes in type 2 diabetic patients. ScientificWorldJournal 2014;2014:694326–1694326.
. Zhao RR, Xu XC, Xu F, et al. Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice. Biochem Biophys Res Commun 2014;448:414–417.
. Alzoubi KH, Khabour OF, Al-Azzam SI, et al. Metformin eased cognitive impairment induced by chronic l-methionine administration: potential role of oxidative stress. Curr Neuropharmacol 2014;12:186–192.
. Chen S, Tang Q, Wang Y, et al. Evidence of metabolic memory-induced neurodegeneration and the therapeutic effects of glucagon-like peptide-1 receptor agonists via Forkhead box class O. Biochim Biophys Acta Mol Basis Dis 2019;1865:371–377.
. Gault VA, Hölscher C. GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes. Peptides 2018;100:101–107.
. Pintana H, Apaijai N, Pratchayasakul W, et al. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci 2012;91:409–414.
. Leech T, Chattipakorn N, Chattipakorn SC. The beneficial roles of metformin on the brain with cerebral ischaemia/reperfusion injury. Pharmacol Res 2019;146:104261.
. Chen F, Dong RR, Zhong KL, et al. Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice. Neuropharmacology 2016;101:123–136.
. Delkhosh-Kasmaie F, Farshid AA, Tamaddonfard E, et al. The effects of safranal, a constitute of saffron, and metformin on spatial learning and memory impairments in type-1 diabetic rats: behavioral and hippocampal histopathological and biochemical evaluations. Biomed Pharmacother 2018;107:203–211.
. Oda SS. Metformin protects against experimental acrylamide neuropathy in rats. Drug Dev Res 2017;78:349–359.
. Ma J, Yu H, Liu J, et al. Metformin attenuates hyperalgesia and allodynia in rats with painful diabetic neuropathy induced by streptozotocin. Eur J Pharmacol 2015;764:599–606.
. Biemans E, Hart HE, Rutten GE, et al. Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes
mellitus using metformin. Acta Diabetol 2015;52:383–393.
. Keshavarzi S, Kermanshahi S, Karami L, et al. Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: the role of CREB/BDNF and Akt/GSK3 signaling pathways. Neurotoxicology 2019;72:74–84.
. Palleria C, Leporini C, Maida F, et al. Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes
. Front Neuroendocrinol 2016;42:76–92.
. Executive summary: standards of medical care in diabetes--2013. Diabetes Care 2013;36 (Suppl 1):S4–10.
. Adedeji HA, Ishola IO, Adeyemi OO. Novel action of metformin in the prevention of haloperidol-induced catalepsy in mice: Potential in the treatment of Parkinson's disease? Prog Neuropsychopharmacol Biol Psychiatry 2014;48:245–251.
. Patil SP, Jain PD, Ghumatkar PJ, et al. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience 2014;277:747–754.
. Katila N, Bhurtel S, Shadfar S, et al. Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease. Neuropharmacology 2017;125:396–407.
. Curry DW, Stutz B, Andrews ZB, et al. Targeting AMPK signaling as a neuroprotective strategy in Parkinson's disease. J Parkinsons Dis 2018;8:161–181.
. Chung MM, Chen YL, Pei D, et al. The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent. Biochim Biophys Acta 2015;1852:720–731.
. Imfeld P, Bodmer M, Jick SS, et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc 2012;60:916–921.
. Kuan YC, Huang KW, Lin CL, et al. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes
mellitus. Prog Neuropsychopharmacol Biol Psychiatry 2017;79:77–83.
. Allard JS, Perez EJ, Fukui K, et al. Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice. Behav Brain Res 2016;301:1–9.
. Ismaiel AAK, Espinosa-Oliva AM, Santiago M, et al. Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system. Toxicol Appl Pharmacol 2016;298:19–30.